Technical validation of a multiplex platform to detect thirty mutations in eight genetic diseases prevalent in individuals of Ashkenazi Jewish descent

Purpose: This study determines the analytic accuracy of a Luminex bead-based commercial analyte-specific reagent for the simultaneous analysis of 30 mutations prevalent in Ashkenazi Jews at eight genetic disease loci.Methods: DNA from 20 samples with known abnormal genotypes were run a total of 109 times. DNA from 820 patients with unknown genotypes submitted for Ashkenazi Jewish testing panels were analyzed using our current laboratory techniques. The 820 samples were then stripped of identifiers, coded, and reanalyzed using the Tm Biosciences (Toronto, Canada) Ashkenazi Jewish panel analyte-specific reagent in a blinded fashion. For the controls, comparisons were made with their known genotypes. For the patient samples, the results of the Tm assay were compared with the results of our current assay. For 24 of the 30 mutations, we had genomic DNA controls or detected patients' samples heterozygous for these mutations.Results: There were no discrepant results in the control or patient samples. In the patient samples, 19,680 genotyping reactions were performed without error in both our laboratory-developed single-disease assays and the Tm multiplex assay. Including the controls, 22,296 genotypes were determined without error.Conclusion: The Tm Biosciences Ashkenazi Jewish analyte-specific reagent is capable of performing accurate analyses of 24 different mutations in eight different genes in a single multiplex reaction and can be used with confidence in the clinical molecular genetics laboratory.

[1]  Weimin Sun,et al.  Cystic fibrosis screening using the College panel: Platform comparison and lessons learned from the first 20,000 samples , 2002, Genetics in Medicine.

[2]  B. Wilfond,et al.  Carrier screening panels for Ashkenazi Jews: Is more better? , 2005, Genetics in Medicine.

[3]  Weimin Sun,et al.  Molecular screening for diseases frequent in Ashkenazi Jews: Lessons learned from more than 100,000 tests performed in a commercial laboratory , 2004, Genetics in Medicine.

[4]  K. Klinger,et al.  Laboratory standards and guidelines for population-based cystic fibrosis carrier screening , 2001, Genetics in Medicine.

[5]  S. Hasnain,et al.  Mutation spectrum of the CYP1B1 gene in Indian primary congenital glaucoma patients. , 2004, Molecular vision.

[6]  J. Lacroix,et al.  Analytical validation of the tag-it high-throughput microsphere-based universal array genotyping platform: application to the multiplex detection of a panel of thrombophilia-associated single-nucleotide polymorphisms. , 2004, Clinical chemistry.

[7]  Weimin Sun,et al.  Extensive sequencing of the cystic fibrosis transmembrane regulator gene: Assay validation and unexpected benefits of developing a comprehensive test , 2003, Genetics in Medicine.

[8]  David D. Clark,et al.  Direct visualization of cystic fibrosis transmembrane regulator mutations in the clinical laboratory setting. , 2004, Clinical chemistry.

[9]  ACOG committee opinion. Number 298, August 2004. Prenatal and preconceptional carrier screening for genetic diseases in individuals of Eastern European Jewish descent. , 2004, Obstetrics and gynecology.

[10]  A. Child,et al.  Sequence analysis and homology modeling suggest that primary congenital glaucoma on 2p21 results from mutations disrupting either the hinge region or the conserved core structures of cytochrome P4501B1. , 1998, American journal of human genetics.

[11]  U. Seligsohn,et al.  Genetic susceptibility to venous thrombosis. , 2001, The New England journal of medicine.

[12]  M. Margaglione,et al.  Coinheritance of the HR2 Haplotype in the Factor V Gene Confers an Increased Risk of Venous Thromboembolism to Carriers of Factor V R506Q (Factor V Leiden) , 1999 .

[13]  C. Strom.  Mutation detection, interpretation, and applications in the clinical laboratory setting. , 2005, Mutation research.

[14]  H. Garchon,et al.  Novel cytochrome P450 1B1 (CYP1B1) mutations in patients with primary congenital glaucoma in France , 2003, Human mutation.